SCHEMBL3012841

SCHEMBL3012841

O=S(=O)(c1ccc(Br)cc1Cl)N1CCN(c2nc(Cc3cccc(Br)c3)cs2)CC1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 1/20 0.40
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
LMNA P02545 2/20 0.39
ALDH1A1 P00352 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MAPT P10636 2/20 0.39
PKM P14618 1/20 0.39
MAPK1 P28482 1/20 0.37
ABL1 P00519 1/20 0.35
RIN1 Q13671 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
USP2 O75604 1/20 0.35
RECQL P46063 1/20 0.35
HSD17B10 Q99714 1/20 0.35
GBA1 P04062 1/20 0.35
TP53 P04637 1/20 0.35
HSD11B1 P28845 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3652532 0.95 TRPV4 (0.41) TRPV4MEN1KMT2ALMNAALDH1A1
SCHEMBL3006210 0.94 TRPV4 (0.47) TRPV4MEN1KMT2ALMNAALDH1A1
SCHEMBL3017760 0.93 TRPV4 (0.45) TRPV4MEN1KMT2ALMNAALDH1A1
SCHEMBL3010373 0.93 SMN1; SMN2 (0.44) TRPV4MEN1KMT2ALMNAALDH1A1
SCHEMBL3016917 0.93 TRPV4 (0.37) TRPV4MEN1KMT2ALMNAALDH1A1
SCHEMBL3013843 0.92 KMT2A (0.43) TRPV4MEN1KMT2ALMNAALDH1A1
SCHEMBL3023052 0.91 TRPV4 (0.38) TRPV4MEN1KMT2ALMNAALDH1A1
SCHEMBL3016449 0.90 LMNA (0.37) TRPV4MEN1KMT2ALMNAALDH1A1
SCHEMBL3015539 0.90 MAPT (0.46) MEN1KMT2ALMNAALDH1A1SMN1; SMN2
SCHEMBL3004891 0.90 TSHR (0.42) MEN1KMT2ALMNAALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA TRPV4 2844/4885MEN1 454/4885KMT2A 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.